ACOR ...... You've all been buried with high priced paper Just like I mentioned in a previous post.
Pretty amazing how they can manip the share price down before the NR 2 days ago and then the huge volume rally ensues
Insiders seldom own shares when a RS is being constructed.....you will always see a rally sometime before it happens.
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
2022-10-19 04:00 ET - News Release
Company Website: https://www.acorda.com/
PEARL RIVER, N.Y. -- (Business Wire)
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the three leading, independent proxy advisory firms - Institutional Shareholder Services (ISS), Glass Lewis and Co, LLC, and Egan-Jones & Co - all recommend that shareholders vote "For" Proposal 2, Reverse Stock Split, at Acorda's Special Meeting of Stockholders, scheduled for November 4, 2022.
"We appreciate the confirmation of the need for and urgency of this proposal," said John P. Kelley, Chair of Acorda's Board of Directors. "The proposal to allow the board to implement a reverse split, if necessary, is critical to ensure that Acorda does not become delisted from Nasdaq. If delisting were to occur, we may be in default on our agreements with our debtholders, and may need to declare bankruptcy."
How Stockholders Can Vote:
Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.
By phone: Call 1-800-967-5051, Monday - Friday 9am to 10pm ET; Saturday 10am - 6pm ET. If you call after hours, leave a message and the call center will call you back the next day.
Online:www.proxyvote.com Please have the control number that was sent to you in the mail.
Mail: Sign, date, and return your proxy card in the postage-paid, stamped envelope provided.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA(TM) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS(TM) pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA(TM) (dalfampridine) Extended Release Tablets, 10 mg.